These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35481285)

  • 21. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control.
    An Y; Jiang W; Kim BYS; Qian JM; Tang C; Fang P; Logan J; D'Souza NM; Haydu LE; Wang XA; Hess KR; Kluger H; Glitza IC; Mahajan A; Welsh JW; Lin SH; Yu JB; Davies MA; Hwu P; Sulman EP; Brown PD; Chiang VLS; Li J
    Radiother Oncol; 2017 Oct; 125(1):80-88. PubMed ID: 28916225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
    Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).
    Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A
    J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
    Chapman PB; Jayaprakasam VS; Panageas KS; Callahan M; Postow MA; Shoushtari AN; Wolchok JD; Betof Warner A
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
    Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability.
    Backlund E; Grozman V; Egyhazi Brage S; Lewensohn R; Lindberg K; Helgadottir H
    Acta Oncol; 2023 Dec; 62(12):1921-1930. PubMed ID: 37966921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single institutional outcomes of whole brain radiotherapy for metastatic melanoma brain metastases.
    Jiang C; Kleber TJ; Switchenko JM; Khan MK
    Radiat Oncol; 2021 Feb; 16(1):31. PubMed ID: 33557890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab.
    Nomura M; Otsuka A; Yoshimura M; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Cancer Chemother Pharmacol; 2018 May; 81(5):823-827. PubMed ID: 29502140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.
    Perez BA; Kim S; Wang M; Karimi AM; Powell C; Li J; Dilling TJ; Chiappori A; Latifi K; Rose T; Lannon A; MacMillan G; Saller J; Grass GD; Rosenberg S; Gray J; Haura E; Creelan B; Tanvetyanon T; Saltos A; Shafique M; Boyle TA; Schell MJ; Conejo-Garcia JR; Antonia SJ
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):425-435. PubMed ID: 33002543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
    Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.
    Koller KM; Mackley HB; Liu J; Wagner H; Talamo G; Schell TD; Pameijer C; Neves RI; Anderson B; Kokolus KM; Mallon CA; Drabick JJ
    Cancer Biol Ther; 2017 Jan; 18(1):36-42. PubMed ID: 27905824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
    Alvarez-Breckenridge C; Markson SC; Stocking JH; Nayyar N; Lastrapes M; Strickland MR; Kim AE; de Sauvage M; Dahal A; Larson JM; Mora JL; Navia AW; Klein RH; Kuter BM; Gill CM; Bertalan M; Shaw B; Kaplan A; Subramanian M; Jain A; Kumar S; Danish H; White M; Shahid O; Pauken KE; Miller BC; Frederick DT; Hebert C; Shaw M; Martinez-Lage M; Frosch M; Wang N; Gerstner E; Nahed BV; Curry WT; Carter B; Cahill DP; Boland GM; Izar B; Davies MA; Sharpe AH; Suvà ML; Sullivan RJ; Brastianos PK; Carter SL
    Cancer Immunol Res; 2022 Aug; 10(8):996-1012. PubMed ID: 35706413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
    Tawbi HA; Forsyth PA; Hodi FS; Lao CD; Moschos SJ; Hamid O; Atkins MB; Lewis K; Thomas RP; Glaspy JA; Jang S; Algazi AP; Khushalani NI; Postow MA; Pavlick AC; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Tarhini AA; Sumbul A; Rizzo JI; Margolin KA
    Neuro Oncol; 2021 Nov; 23(11):1961-1973. PubMed ID: 33880555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.